Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeOne Medicines Ltd ( (HK:6160) ) has provided an update.
BeOne Medicines Ltd. has convened its 2026 annual general meeting of shareholders for June 11, 2026, in Zurich, setting May 22, 2026, as the record date for eligibility to vote. The company, which is listed in the U.S., Hong Kong and Shanghai, is coordinating the meeting across these markets to accommodate its broad shareholder base and regulatory obligations.
The group will primarily distribute proxy materials and its 2025 annual report via the internet, with printed copies going only to STAR Market RMB-shareholders or investors who request them or where local rules require. This digital-first approach is intended to streamline access for holders of Swiss-registered shares, Hong Kong–listed shares and Nasdaq-traded ADSs, while providing clear instructions on voting, meeting participation and access to financial documents.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.
More about BeOne Medicines Ltd
BeOne Medicines Ltd. is a biopharmaceutical company listed on Nasdaq, the Hong Kong Stock Exchange and Shanghai’s STAR Market, with its operations and shareholder register anchored in Switzerland. The company targets global capital markets through ordinary shares and ADSs to fund its research-driven medicines portfolio and engage a geographically diverse investor base.
Average Trading Volume: 3,809,861
Technical Sentiment Signal: Buy
Current Market Cap: HK$269B
See more data about 6160 stock on TipRanks’ Stock Analysis page.